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conducted every 4 weeks at the hospital. A male and two 
female subjects were withdrawn from this study because 
of pregnancy or urinary tract infection so the final num-
ber of subjects was 37. Informed consent was obtained 
from qualified individuals. The baseline characteristics of 
subjects of each group were not different statistically. No 
adverse events were observed throughout the trial period 
except for a few symptoms like itchiness or headache 
which were self-reported from subjects, but the relation-
ships with the test material were denied by the principle 
investigator.
On the 24-h urine test, almost no markers changed, but 
there was a significant change in total l-hydroxyproline 
excretions in the 2000 mg l-hydroxyproline group com-
pared to control group at the point of 8 weeks after first 
intake. Moreover, oxalic acid levels also increased sig-
nificantly in the 2000 mg group at the point of 8 and 
12 weeks after first intake. However, all values returned to 
basal values after 4 weeks from the last l-hydroxyproline 
intake (Table 1). Various dietary factors can change urine 
oxalate excretion; one is a high-protein diet. Many studies 
have addressed urinary oxalate excretion after high-protein 
intake, but conclusions are still uncertain. For example, 
Knight et al. [1] not only showed significant changes in uri-
nary oxalate with 5 and 10 g of gelatine administered to 
healthy subjects, but also indicated that the high-protein 
diet did not influence total daily urinary oxalate excretion 
[2]. Collagen contains approximately 10 % of l-hydroxy-
proline, and the daily turnover of collagen in humans is 
estimated to be 2–3 g/day so the metabolism of l-hydroxy-
proline will be 240–420 mg [1]. In this study, the urinary 
oxalate level following 500 or 1000 mg/day l-hydroxy-
proline ingestion did not change compared with control 
but 2000 mg/day l-hydroxyproline ingestion increased the 
urinary oxalate excretion, but the values did not exceed 
As calcium oxalate is the most common constituent of 
urinary stones animal model of the urolithiasis has been 
established by feeding l-hydroxyproline, an endoge-
nous precursor of oxalate. However, the influence of oral 
l-hydroxyproline on human urinary oxalate excretion has 
not been clearly demonstrated. We herein report a clini-
cal study examining the influence of daily ingestion of 
l-hydroxyproline on urinary oxalate levels with a focus on 
measuring oxalic acid excreted in the urine.
In detail, we performed a single-blind, parallel designed 
study at Sta. Rosa Hospital and Medical Center, Philip-
pines. This study was approved by the hospital review 
board and was in compliance with the Declaration of Hel-
sinki. Forty healthy subjects (20 males and 20 females, 
33.4 ± 9.4 years of age, who has no history of kidney dis-
ease) were divided into 4 groups with 10 subjects in each 
group with same sex ratio. l-Hydroxyproline doses of 0, 
500, 1000 and 2000 mg were taken daily after breakfast 
for 12 weeks. Prior to and during each scheduled exami-
nation, subjects were reminded to refrain from intake of 
oxalate-rich foods and to drink more than 1 L of water 
per day. Medical interviews, physical examinations, vital 
sign measurements, anthropometric measurements, blood 
examinations and 24-h urine sample collections were 
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Table 1  Urinalysis results of 24-h urine sample
Urinalysis of 24-h urine Subjects (n = 37: 19 male, 18 female)
l-Hydroxyproline
0 mg/day  
(n = 10: 5 M, 5 F)
500 mg/day  
(n = 9: 5 M, 4 F)
1000 mg/day  
(n = 10, 5 M, 5 M)
2000 mg/day  
(n = 8: 4 M, 4 F)
Na (g/day)
 Pre-intake 3.1 ± 1 2.8 ± 1.2 3.2 ± 0.9 3 ± 0.8
 4 weeks after first intake 3 ± 1 3.5 ± 1.2 3.6 ± 1.1 4 ± 0.6
 8 weeks after first intake 2.3 ± 1 1.9 ± 0.8 3 ± 1 2.7 ± 0.7
 12 weeks after first intake 3.3 ± 1 3.6 ± 1.2 3.3 ± 0.9 3.9 ± 1.3
 4 weeks after final intake 3.5 ± 1.6 3.1 ± 0.7 3.4 ± 0.8 3.3 ± 1.2
K (g/day)
 Pre-intake 0.67 ± 0.27 0.66 ± 0.28 0.82 ± 0.25 0.72 ± 0.24
 4 weeks after first intake 0.67 ± 0.2 0.6 ± 0.27 0.7 ± 0.22 0.81 ± 0.25
 8 weeks after first intake 0.56 ± 0.19 0.55 ± 0.3 0.56 ± 0.22 0.61 ± 0.18
 12 weeks after first intake 0.68 ± 0.29 0.68 ± 0.24 0.61 ± 0.24 0.71 ± 0.28
 4 weeks after final intake 0.7 ± 0.3 0.59 ± 0.29 0.67 ± 0.19 0.66 ± 0.3
Ca (g/day)
 Pre-intake 0.16 ± 0.07 0.13 ± 0.06 0.12 ± 0.04 0.11 ± 0.04
 4 weeks after first intake 0.19 ± 0.08 0.16 ± 0.04 0.17 ± 0.05 0.17 ± 0.05
 8 weeks after first intake 0.12 ± 0.04 0.1 ± 0.03 0.12 ± 0.05 0.12 ± 0.04
 12 weeks after first intake 0.14 ± 0.08 0.15 ± 0.08 0.13 ± 0.05 0.14 ± 0.07
 4 weeks after final intake 0.13 ± 0.07 0.12 ± 0.09 0.12 ± 0.05 0.13 ± 0.04
Mg (g/day)
 Pre-intake 0.04 ± 0.02 0.05 ± 0.03 0.06 ± 0.02 0.04 ± 0.01
 4 weeks after first intake 0.05 ± 0.02 0.05 ± 0.02 0.07 ± 0.02 0.06 ± 0.02
 8 weeks after first intake 0.04 ± 0.01 0.05 ± 0.02 0.05 ± 0.01 0.05 ± 0.02
 12 weeks after first intake 0.05 ± 0.02 0.06 ± 0.02 0.06 ± 0.01 0.05 ± 0.02
 4 weeks after final intake 0.04 ± 0.01 0.05 ± 0.02 0.06 ± 0.01* 0.05 ± 0.02
Inorganic phosphorus (g/day)
 Pre-intake 0.47 ± 0.21 0.41 ± 0.18 0.52 ± 0.12 0.47 ± 0.1
 4 weeks after first intake 0.48 ± 0.18 0.45 ± 0.12 0.54 ± 0.08 0.55 ± 0.16
 8 weeks after first intake 0.57 ± 0.2 0.49 ± 0.1 0.6 ± 0.22 0.59 ± 0.13
 12 weeks after first intake 0.55 ± 0.27 0.51 ± 0.2 0.54 ± 0.13 0.51 ± 0.17
 4 weeks after final intake 0.48 ± 0.14 0.41 ± 0.18 0.51 ± 0.16 0.49 ± 0.16
Uric acid (g/day)
 Pre-intake 0.19 ± 0.06 0.15 ± 0.06 0.17 ± 0.08 0.13 ± 0.04
 4 weeks after first intake 0.19 ± 0.05 0.17 ± 0.07 0.17 ± 0.06 0.15 ± 0.04
 8 weeks after first intake 0.12 ± 0.03 0.09 ± 0.03 0.12 ± 0.06 0.11 ± 0.04
 12 weeks after first intake 0.15 ± 0.05 0.13 ± 0.03 0.14 ± 0.04 0.14 ± 0.06
 4 weeks after final intake 0.16 ± 0.03 0.11 ± 0.03 0.14 ± 0.05 0.12 ± 0.05
Urea nitrogen (g/day)
 Pre-intake 6.14 ± 2.78 5.9 ± 2.45 6.7 ± 2.02 5.67 ± 1.6
 4 weeks after first intake 6.74 ± 2.44 6.29 ± 1.63 7.17 ± 1.37 7.42 ± 2.08
 8 weeks after first intake 7.04 ± 2.65 6.53 ± 1.68 7.19 ± 1.9 7.71 ± 1.23
 12 weeks after first intake 6.84 ± 2.92 6.78 ± 1.34 6.96 ± 1.58 6.87 ± 2.06
 4 weeks after final intake 6.08 ± 1.43 6.15 ± 1.71 6.73 ± 1.24 6.05 ± 2.34
Creatinine (g/day)
 Pre-intake 0.94 ± 0.42 0.82 ± 0.33 1 ± 0.26 0.93 ± 0.28
 4 weeks after first intake 1.05 ± 0.37 0.93 ± 0.21 1.14 ± 0.27 1.13 ± 0.33
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the level of stone forming individuals with a mean oxa-
late excretion 40 mg/day [2]. As noted, there are various 
opinions on the association of dietary and urinary oxalate. 
Recently, it was reported that the Dietary-Approaches to 
Stop Hypertension (DASH)-style diet is more effective 
in reducing calcium oxalate supersaturation than a low-
oxalate diet, although it includes a lot of fruits and vegeta-
bles which contain much oxalate [3]. Thus, the influence 
of the diet in conjunction with oxalate is still unclear in 
human metabolism. Moreover, we found no accumulation 
of l-hydroxyproline and oxalate in the withdrawal period 
same as the animal model. The metabolic significance of 
l-hydroxyproline is still unclear and further investigation is 
warranted.
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Urinalysis of 24-h urine Subjects (n = 37: 19 male, 18 female)
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0 mg/day  
(n = 10: 5 M, 5 F)
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(n = 9: 5 M, 4 F)
1000 mg/day  
(n = 10, 5 M, 5 M)
2000 mg/day  
(n = 8: 4 M, 4 F)
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